FDA Sets Review Timeline for MEDIBEACON Patent Extension
Published Date: 1/5/2026
Notice
Summary
The FDA has officially set the review period for MEDIBEACON, a medical device, which helps the company apply for extra patent time. This means the makers can potentially extend their patent protection, giving them more time to benefit financially. Anyone interested has until March 6, 2026, to share their thoughts with the FDA.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 0 costs, 2 mixed.
FDA Sets Patent Review Period
The FDA determined MEDIBEACON's regulatory review period is 4,175 days in total — 3,598 days in the testing phase and 577 days in the approval phase. That determination establishes the maximum potential length of a patent extension; the applicant seeks 5 years of patent term extension (the PMA was approved January 17, 2025).
MEDIBEACON Approval & Use Limits
MEDIBEACON was approved (PMA P230019) on January 17, 2025 to assess glomerular filtration rate (GFR) in adult patients by noninvasively monitoring fluorescent light from an injected tracer. The device is validated in patients with stable renal function but is not approved for use in patients with GFR 120 ml/min/1.73m2, patients on dialysis, or anuric patients, and it is not intended to diagnose acute kidney injury; the TGFR Sensor and Lumitrace injection are single-use and used only with the MediBeacon TGFR system.
Right to Petition or Comment by March 6, 2026
Anyone who believes the dates published are incorrect may submit electronic or written comments and request a redetermination, and any interested person may petition FDA under 21 CFR 60.24 and 60.30 to challenge whether the applicant acted with due diligence; comments and petitions will be accepted through 11:59 p.m. Eastern Time on March 6, 2026. Petitions must be timely, follow specified filing rules, contain sufficient facts, and certify service on the patent applicant.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
Previous / Next Documents
Previous: 2025-24267 — Determination of Regulatory Review Period for Purposes of Patent Extension; IZERVAY
The FDA has officially set the review period for IZERVAY, a human drug, so its patent can be extended. This affects the drug’s makers, who now have clear deadlines to challenge or confirm these dates by early 2026. If all goes well, the patent extension could give them more time to protect their invention and potentially earn more money.
Next: 2025-24269 — Determination of Regulatory Review Period for Purposes of Patent Extension; BRENZAVVY
The FDA has officially set the review period for the drug BRENZAVVY, which helps the company apply for extra patent time. This affects the drug maker and anyone watching patent rules, giving a chance to challenge dates or the company’s effort by early 2026. It’s all about making sure the patent clock is fair and accurate, potentially impacting how long the drug stays exclusive on the market.